The Journal of Urology 2002: Vol 167 Index

67 Pages·2002·23.2 MB·English

_ THE JOURNAL OF UroLocy® Vol. 167, 2670-2681, June 2002
Copyright © 2002 by American Urotoaicat Association, Inc.® Printed in U.S.A.
Benigr
a-blo
SUBJECT INDEX TO ABSTRACTS IN VOLUME 167 fins
hy}
drugs
Abdomen, computed tomography of, pitfalls in (Urban and Fish- after laparoscopy (Mginiche et al), 800 FGF
man), 417 ; presurgical preemptive (Kato et al), 800 holm:
Abdominoscrotal hydrocele, in children, frequency of (Avolio et third-generation lithotripter outcome and (Eichel et al), 2318 hype!
al), 1920 Aneuploidy, in sperm of men treated with chemotherapy (De Mas IL-8-
Acetyl-L-carnitine, for Peyronie’s disease (Biagiotti and Cavallini), et al), 785 overa
788 Angiogenesis, bladder transitional cell carcinoma recurrence and quali
Acidic protein, immunosuppressive, as marker for renal cell carci- (Sagol et al), 2293 (Ke
noma staging and survival (Miyata et al), 2322 Angiography, magnetic resonance, of penis (Pretorius et al): see (va
Acrosome reaction, antisperm antibodies and (Bohring et al), 785 Magnetic resonance angiography serul
Acute phase reactants, as markers for renal cell carcinoma stag- Angiotensin II, plasma level of, in erectile dysfunction (Becker et TUR!
ing and survival (Miyata et al), 2322 al), 2302
Adenoviral vectors, in nitric oxide synthase gene therapy for erec- Anorecta! malformations, advances in (Pefia and Hong), 1918 uring
tile dysfunction (Tirney et al), 2301 Antibiotic prophylaxis vitan
Adrenal glands, renal cell carcinoma metastasis to, incidence and for combined urodynamics and cystourethroscopy (Cundiff et al),
outcome of( Paul et al), 1554 430 Bicalu
Adrenal hyperplasia, congenital: see Congenital adrenal hyperpla- in permanent prostate brachytherapy (Dicker et al), 430 after
sia Antibiotic resistance, in urinary tract infection, in Iceland (Olaf- recul
Adrenal insufficiency, megestrol-induced (Goodman and Cagli- sson et al), 429 Biliary
ero), 2652 Antibiotics
Adrenal tuberculosis, autopsy experiences in (Lam and Lo), 1552 for asymptomatic bacteriuria in pregnancy (Smaill), 1932
Adrenalectomy, retroperitoneal laparoscopic (Soulié et al), 806 intravenous, duration of for pyelonephritis in children, renal scar- Bioma
a-Adrenergic blockers ring and (Benador et al), 1929 for p
discontinuation in BPH for prostate inflammation, PSA and prostate cancer screening he;
finasteride and doxazosin therapy and (Baldwin et al), 1935 after (Karazanashvili and Managadze), 1932 sec
hypotension-related adverse events and (Chrischilles et al), 1936 Antibodies, against sperm, acrosome reaction and (Bohring et al),
effects on ejaculation, penile erection, and pelvic thrusting (Yon- 785 str
ezawa et al), 2307 Anti-human globulin enhanced cytotoxicity, in renal trans-
Age/aging: see also Geriatric patients . plant recipients (Karpinski et al), 2664 for ré
erectile and ejaculatory dysfunction and (Blanker et al), 2299 Apolipoproteins, blood. levels of, transdermal testosterone and
longitudinal study of, predicting prostate cancer risk from PSA (Whitsel et al), 793 Bioma
level in (Fang et al), 1907 Apomorphine, sublingual, for erectile dysfunction (Mulhall et al),
prostate cancer and (Potter et al), 408 791
PSA testing and, patterns among primary care physicians (Collins Arsenic in drinking water, in Taiwan, transitional cell carcinoma
et al), 808 and (Chiou et al), 2290
quality ofl ife and urinary tract symptoms and, in BH (Eckhardt Arterial stiffness, after induced hypogonadism for prostate cancer
~ et al), 434 (Smith et al), 1914
semen quality and fertility and (Kidd et al), 2298 Autofluorescence imaging, of bladder cancer (Frimberger et al),
Allograft protection, FTY720 and (Brinkmann et al), 2663 1926 of tr:
Allograft rejection Autotransplantation, laparoscopic nephrectomy with, for iatro- uretl
late, after 10-year cyclosporine treatment (Marcén et al), 1563 genic ureteral injury (Shekarriz et al), 2316 Bladd
live versus cadaveric donor and (Pratschke et al), 2665 neur
oligoarray analysis of genes in (Akalin et al), 2666
steroid-free immunosuppression in (Cole et al), 1562 Bacillus Calmette-Guérin over:
Allopurinol, for chronic prostatitis (Collins and Wilt), 1933 action mechanisms of (Prescott et al), 777 rupt
Alprostadil, intracavernosal, for erectile dysfunction in diabetes for bladder cancer, urinary fibronectin levels after (Danisman et tran:
(Heaton et al), 2312 al), 777 _ an
Amantadine, sexual behavior and (Ferraz et al), 2301 intrarenal, for upper urinary tract carcinoma (Okubo et al), 2315 hy
Androgen ablation, after radiation therapy failure, practice pat- killer cells activated by, in vitro generation of (Brandau et al), 778 mi
terns of urologists and radiation oncologists in (Sylvester et Bacteriuria, asymptomatic pd
al), 2325 in diabetic women (Geerlings et al), 428 rei
Androgen deficiency, in older men, transdermal dihydrotestoster- in pregnancy
one gel for (Ly et al), 2324 antibiotics for (Smaill), 1932
Androgen deprivation therapy, for prostate cancer duration of treatment for (Villar et al), 1931
(Bondy et al), 811 Balloon cautery endoureterotomy, for ureteral strictures after Bladd
bone loss during, prevention with pamidronate (Smith et al), 1912 renal transplantation (Schwartz et al), 2317 auto
hydrogel histrelin implant for (Schlegel et al), 1913 Barbagli patch urethroplasty, for bulbar urethra (Andrich et al),
recurrence after, androgen receptor mechanisms in (Gregory et al), 1563 BCG
2650 Basic fetoprotein, as marker for renal cell carcinoma staging and cyst
Androgen receptor, CAG repeats in survival (Miyata et al), 2322
male infertility and (Mifsud et al), 783 bax immunoreactivity, as predictor of response and outcome of diag
sperm concentration and (von Eckardstein et al), 783 chemotherapy for metastatic germ cell testicular tumors
Androgen-independent prostate cancer, thalidomide for (Figg (Baltaci et al), 1548 follo
et al), 1914 BCG: see Bacillus Calmette-Guérin inva
Anesthesia bel-2, as predictor of response and outcome of chemotherapy for
local infiltration of metastatic germ cell testicular tumors (Baltaci et al), 1548 met:
2670
_ THE JOURNAL OF UroLocy® Vol. 167, 2670-2681, June 2002
Copyright © 2002 by American Urotoaicat Association, Inc.® Printed in U.S.A.
Benigr
a-blo
SUBJECT INDEX TO ABSTRACTS IN VOLUME 167 fins
hy}
drugs
Abdomen, computed tomography of, pitfalls in (Urban and Fish- after laparoscopy (Mginiche et al), 800 FGF
man), 417 ; presurgical preemptive (Kato et al), 800 holm:
Abdominoscrotal hydrocele, in children, frequency of (Avolio et third-generation lithotripter outcome and (Eichel et al), 2318 hype!
al), 1920 Aneuploidy, in sperm of men treated with chemotherapy (De Mas IL-8-
Acetyl-L-carnitine, for Peyronie’s disease (Biagiotti and Cavallini), et al), 785 overa
788 Angiogenesis, bladder transitional cell carcinoma recurrence and quali
Acidic protein, immunosuppressive, as marker for renal cell carci- (Sagol et al), 2293 (Ke
noma staging and survival (Miyata et al), 2322 Angiography, magnetic resonance, of penis (Pretorius et al): see (va
Acrosome reaction, antisperm antibodies and (Bohring et al), 785 Magnetic resonance angiography serul
Acute phase reactants, as markers for renal cell carcinoma stag- Angiotensin II, plasma level of, in erectile dysfunction (Becker et TUR!
ing and survival (Miyata et al), 2322 al), 2302
Adenoviral vectors, in nitric oxide synthase gene therapy for erec- Anorecta! malformations, advances in (Pefia and Hong), 1918 uring
tile dysfunction (Tirney et al), 2301 Antibiotic prophylaxis vitan
Adrenal glands, renal cell carcinoma metastasis to, incidence and for combined urodynamics and cystourethroscopy (Cundiff et al),
outcome of( Paul et al), 1554 430 Bicalu
Adrenal hyperplasia, congenital: see Congenital adrenal hyperpla- in permanent prostate brachytherapy (Dicker et al), 430 after
sia Antibiotic resistance, in urinary tract infection, in Iceland (Olaf- recul
Adrenal insufficiency, megestrol-induced (Goodman and Cagli- sson et al), 429 Biliary
ero), 2652 Antibiotics
Adrenal tuberculosis, autopsy experiences in (Lam and Lo), 1552 for asymptomatic bacteriuria in pregnancy (Smaill), 1932
Adrenalectomy, retroperitoneal laparoscopic (Soulié et al), 806 intravenous, duration of for pyelonephritis in children, renal scar- Bioma
a-Adrenergic blockers ring and (Benador et al), 1929 for p
discontinuation in BPH for prostate inflammation, PSA and prostate cancer screening he;
finasteride and doxazosin therapy and (Baldwin et al), 1935 after (Karazanashvili and Managadze), 1932 sec
hypotension-related adverse events and (Chrischilles et al), 1936 Antibodies, against sperm, acrosome reaction and (Bohring et al),
effects on ejaculation, penile erection, and pelvic thrusting (Yon- 785 str
ezawa et al), 2307 Anti-human globulin enhanced cytotoxicity, in renal trans-
Age/aging: see also Geriatric patients . plant recipients (Karpinski et al), 2664 for ré
erectile and ejaculatory dysfunction and (Blanker et al), 2299 Apolipoproteins, blood. levels of, transdermal testosterone and
longitudinal study of, predicting prostate cancer risk from PSA (Whitsel et al), 793 Bioma
level in (Fang et al), 1907 Apomorphine, sublingual, for erectile dysfunction (Mulhall et al),
prostate cancer and (Potter et al), 408 791
PSA testing and, patterns among primary care physicians (Collins Arsenic in drinking water, in Taiwan, transitional cell carcinoma
et al), 808 and (Chiou et al), 2290
quality ofl ife and urinary tract symptoms and, in BH (Eckhardt Arterial stiffness, after induced hypogonadism for prostate cancer
~ et al), 434 (Smith et al), 1914
semen quality and fertility and (Kidd et al), 2298 Autofluorescence imaging, of bladder cancer (Frimberger et al),
Allograft protection, FTY720 and (Brinkmann et al), 2663 1926 of tr:
Allograft rejection Autotransplantation, laparoscopic nephrectomy with, for iatro- uretl
late, after 10-year cyclosporine treatment (Marcén et al), 1563 genic ureteral injury (Shekarriz et al), 2316 Bladd
live versus cadaveric donor and (Pratschke et al), 2665 neur
oligoarray analysis of genes in (Akalin et al), 2666
steroid-free immunosuppression in (Cole et al), 1562 Bacillus Calmette-Guérin over:
Allopurinol, for chronic prostatitis (Collins and Wilt), 1933 action mechanisms of (Prescott et al), 777 rupt
Alprostadil, intracavernosal, for erectile dysfunction in diabetes for bladder cancer, urinary fibronectin levels after (Danisman et tran:
(Heaton et al), 2312 al), 777 _ an
Amantadine, sexual behavior and (Ferraz et al), 2301 intrarenal, for upper urinary tract carcinoma (Okubo et al), 2315 hy
Androgen ablation, after radiation therapy failure, practice pat- killer cells activated by, in vitro generation of (Brandau et al), 778 mi
terns of urologists and radiation oncologists in (Sylvester et Bacteriuria, asymptomatic pd
al), 2325 in diabetic women (Geerlings et al), 428 rei
Androgen deficiency, in older men, transdermal dihydrotestoster- in pregnancy
one gel for (Ly et al), 2324 antibiotics for (Smaill), 1932
Androgen deprivation therapy, for prostate cancer duration of treatment for (Villar et al), 1931
(Bondy et al), 811 Balloon cautery endoureterotomy, for ureteral strictures after Bladd
bone loss during, prevention with pamidronate (Smith et al), 1912 renal transplantation (Schwartz et al), 2317 auto
hydrogel histrelin implant for (Schlegel et al), 1913 Barbagli patch urethroplasty, for bulbar urethra (Andrich et al),
recurrence after, androgen receptor mechanisms in (Gregory et al), 1563 BCG
2650 Basic fetoprotein, as marker for renal cell carcinoma staging and cyst
Androgen receptor, CAG repeats in survival (Miyata et al), 2322
male infertility and (Mifsud et al), 783 bax immunoreactivity, as predictor of response and outcome of diag
sperm concentration and (von Eckardstein et al), 783 chemotherapy for metastatic germ cell testicular tumors
Androgen-independent prostate cancer, thalidomide for (Figg (Baltaci et al), 1548 follo
et al), 1914 BCG: see Bacillus Calmette-Guérin inva
Anesthesia bel-2, as predictor of response and outcome of chemotherapy for
local infiltration of metastatic germ cell testicular tumors (Baltaci et al), 1548 met:
2670
2 2002 SUBJECT INDEX TO ABSTRACTS 2671
U.S.A.
Benign prostatic hyperplasia muscle-invasive, chemoradiotherapy for (Arias et al), 2297
a-blockade discontinuation in progression from superficial to invasive, p27”! and cyclin E levels
finasteride and doxazosin therapy and (Baldwin et al), 1935 and (Kamai et al), 2290
hypotension-related adverse effects and (Chrischilles et al), 1936 recurrence of, detection with ImmunoCyt test (Vriesema et al),
drugs for, cardiovascular effects of (Souverein et al), 435 1924
FGF receptors in (Boget et al), 1938 urinary markers for (Mungan et al), 774
holmium laser prostate resection of (Fraundorfer et al), 811 Bladder cancer cells, doxorubin chemosensitivity of, MMAC1/
hyperinsulinemia and (Hammarsten and Hégstedt), 431 PTEN induction of (Tanaka et al), 778
» Mas IL-8-induced FGF-2 in (Giri and Ittmann), 435 Bladder cell carcinoma, urothelial, UBC-ELISA test versus
overactive bladder with (Knutson et al), 2660 NMP22 test for (Mian et al), 775
2 and quality of life and urinary tract symptoms in Bladder mechanics, effect of detrusor muscle regeneration on (Fre-
(Eckhardt et al), 434 deriksen et al), 2659
): see (van Venrooij et al), 434 Bladder neck obstruction
serum:urinary PSA ratio in (Hillenbrand et al), 436 purinoceptor expression in (O’Reilly et al), 2656
cer et TURP versus laser vaporization for, economics and (Keoghane et in women (Patel and Nitti), 2658
al), 2323 Bladder substitution, tissue engineering for
urinary retention in (Roehrborn et al), 1936 (Atala), 1556
vitamin D receptor and 17-hydroxylase gene polymorphisms in skeletal muscle transfer with
t al), (Schatzl et al), 433 (Ninkovic et al), 2659
Bicalutamide (Casodex), for prostate cancer (Schoeller et al), 2659
after failed hormone therapy (Kucuk et al), 415 Bladder tumor antigen (BTA) stat test
Olaf- recurrence and (Wirth et al), 414 false-positive, in bladder cancer follow-up (Raitanen et al), 773
Biliary surgery, ultrasonic coagulating shears, LigaSure vessel as tumor marker for upper tract transitional cell carcinoma
sealer, and surgical clip application in (Matthews et al), (Walsh et al), 1923.
2314 Bleomycin, for testicular tumor, sperm aneuploidy after (De Mas et
scar- Biomarkers al), 785
for prostate cancer a-Blockers: see a-Adrenergic blockers
ening hepsin as (Magee et al), 2328 Blood transfusion, for myocardial infarction in elderly patients
sequence databases and microarray approaches to (Grouse et (Wu et al), 1922
t al), al), 2327 Blunt trauma, bladder rupture after, imaging of (Morey et al), 2667
stromal and epithelial hyaluronic acid and HYAL1 hyaluroni- Body composition, after induced hypogonadism for prostate cancer
rans- dase as (Lokeshwar et al), 2330 (Smith et al), 1914
for renal cell carcinoma Bone density, in renal transplant recipients (Giannini et al), 2665
and staging and survival and (Miyata et al), 2322 Bone loss
Biomaterial, for urethral repair, acellular collagen matrix for (Chen during androgen deprivation therapy, prevention with pamidr-
t al), et al), 1564 onate (Smith et al), 1912
Biopsy after GnRH agonists for prostate cancer (Stoch et al), 415
noma prostate Bone scans, routine, indications for (Wymenga et al), 410
after brachytherapy, PSA rise and Bowel occlusion, after laparoscopy (Romagnolo and Minelli), 802
ancer (Grimm et al), 412 BPH: see Benign prostatic hyperplasia
(Smathers et al), 412 : Brachytherapy
t al), before orthotopic neobladder substitution (Bulbul et al), 424 PSA rise and repeat prostate biopsy after (Smathers et al), 412
of transition zone, indications for (Liu et al), 409 transperineal interstitial permanent prostate, antibiotic prophy-
atro- urethral, before orthotopic neobladder substitution (Bulbul et al), 424 laxis in (Dicker et al), 430
Bladder Brain death, of donor, renal transplant rejection and (Pratschke et
neuromodulation of, in spinal cord-injured patient (Kirkham et al), al), 2665
1555 Breast cancer screening, physician-patient discussions of (Dunn
overactive, in BPH (Knutson et al), 2660 et al), 2326
rupture of, after blunt trauma, imaging of (Morey et al), 2667 BTA (bladder tumor antigen) stat test
an et transitional cell carcinoma of false-positive, in bladder cancer follow-up (Raitanen et al), 773
and arsenic in drinking water (Chiou et al), 2290 Bulbar urethra, Barbagli patch urethroplasty for (Andrich et al),
2315 hypericin photodynamic activity in (Zupk6 et al), 2296 1563 °
, 178 microsatellite instability in (Bonnal et al), 776 Bupivacaine, local infiltration of, presurgical preemptive (Kato et
p53 prognostic value in (Shariat et al), 776 al), 800
recurrent . Buschke-Lowenstein tumors of penis, glansectomy for (Davis
angiogenesis and (Sagol et al), 2293 and Schellhammer), 2303
p53 gene alterations and (Friedrich et al), 2291
rate of, intravesical chemotherapy and (Huncharek et al), 780 CAG repeats, in androgen receptor
after Bladder cancer male infertility and (Mifsud et al), 783
autofluorescence imaging and fluorescence endoscopy of (Frim- sperm concentration and (von Eckardstein ei al), 783
t al), berger et al), 1926 CAG/CTG repeats, in testicular germ cell cancer (Ono et al), 2646
BCG for, vrinary fibronectin levels after (Danisman et al), 777 Cancer: see also sites and types of cancer
rand cystectomy for, adjuvant chemotherapy after (Sylvester and Stern- molecular staging of (Cote), 771
berg), 779 Cancer screening
ne of diagnosis of, DNA image cytometry and urinary cytology in (Planz in elderly patients (Walter and Covinsky), 422
mors et al), 771 informed choice in (Welch), 422
follow-up of, false-positive BTA stat test in (Raitanen et al), 773 physician-patient discussions of
invasive, molecular genetic diagnosis of (Krause et al), 770 (Dunn et al), 2326
y for management of, second opinion pathology and (Coblentz et al), 780 (Frosch et al), 2326
1548 metastasis to lymph nodes, cytokeratin 7 and 20 in (Jiang et al), Canine feces, as reservoir of extraintestinal pathogenic Escherichia
2294 coli (Johnson et al), 427
-2672 SUBJECT INDEX TO ABSTRACTS
Capnoperitoneum, during laparoscopic cholecystectomy (Dexter et Circumcision subto
al), 799 misclassification of, infections and (Disekker et al), 1929
Capsular incision, in radical retropubic prostatectomy, prognosis of newborns, effect on urinary tract infection cost and incidence Cystiti
and (Barocas et al), 1910 (Schoen et al), 1930 hema
Cardiovascular system, BPH drug effects on (Souverein et al), 435 Cisplatin name
Casodex (bicalutamide) neurotoxicity of, in metastatic germ cell tumors (von Schlippe et querc
for local prostate cancer, recurrence and (Wirth et al), 414 al), 2649 Cyston
for prostate cancer, after failed hormone therapy (Kucuk et al), 415 for testicular tumor, sperm aneuploidy after (De Mas et al), 785
Caspase, adenoviral transfer of, in gene therapy for prostate cancer Cis-retinoic acid, for advanced renal cell carcinoma (Valsham- Cystop
(Shariat et al), 2329 payan et al), 2323 Cystos
Cavernosal artery, penile, prostaglandin E1 instillation versus Clitoral neuropathy, in female neurogenic sexual dysfunction (Sax
injection and (Kim et al), 786 et al), 793 Cystou
Cavernous plasma, testosterone in, during erectile dysfunction Coagulating shears, ultrasonic, in biliary surgery (Matthews et
(Becker et al), 787 al), 2314 Cytoke
Cell cycle regulator, in Peyronie’s disease (Mulhall et al), 2311 Cochrane review in ble
Chemoradiotherapy, for muscle-invasive bladder cancer (Arias et of allopurinol for chronic prostatitis (Collins and Wilt), 1933 urina
al), 2297 of asymptomatic bacteriuria in pregnancy
Chemotherapy antibiotics for (Smaill), 1932 Deep \
adjuvant, after cystectomy for bladder cancer (Sylvester and duration of treatment for (Villar et al), 1931
Sternberg), 779 of cranberries to prevent urinary tract infection (Jepson et al), Deflaz:
for germ cell tumors, hCG and a-fetoprotein serum markers in 1930 Detrus
(Mazumdar et al), 1551 Collagen, injectable, for urinary incontinence in women (Her- involi
intravesical, bladder transitional cell carcinoma recurrence rate schorn), 1560
and (Huncharek et al), 780 Collagen matrix, acellular, for urethral repair (Chen et al), 1564
for metastatic germ cell testicular tumors, predictors of response Colon pouch, for urinary diversion after pelvic irradiation (Leiss-
and outcome after (Baltaci et al), 1548 ner et al), 425
for nonseminomatous germ cell tumors, viable malignant cells Community-acquired urinary tract infections, in women, drug
after (Fizazi et al), 1550 resistancei n (Gupta et al), 1927 cigar’
for testicular tumor, sperm aneuploidy after (De Mas et al), 785 Computed tomography intra
Children: see also Infants; Newborns of abdomen and pelvis, pitfalls in (Urban and Fishman), 417 undis
abdominoscrotal hydrocele in, frequency of (Avoho et al), 1920 compression, of ureters (Heneghan et al), 416 in we
chordee in, corrective surgery for, penile sensation after (Ghane in pheochromocytoma localization (Berglund et al), 2651 Dialys
et al), 419 : stone fragility and (Dretler and Spencer), 417 Dihydi
epididymitis in, investigation after first episode (Cappele et al), 420 three-dimensional, of genitourinary tract (Leder and Nelson), 417
gonadal and nongonadal germ cell tumors in, common precursor _ in urothelial carcinoma staging, limitations in (Scolieri et al), 423 Diuret
cell for (Schneider et al), 2647 Congenital abnormalities, in children of men treated with chemo-
hypospadias in therapy (De Mas et al), 785 DMSA:
re-operative Snodgrass incised plate urethroplasty for (Shan- Corgenital adrenal hyperplasia, adult males with, long term DNA i
berg et al); 421 outcome of (Cabrera et al), 782
tubularized-incised plate repair of, uroflowmetry after (Marte et Congenital chordee, corrective surgery for, penile sensation after Doxaz
al), 421 (Ghanem et al), 419
older symptomatic, endopyelotomy in (Nicholls et al), 1916 Contractile proteins, effect of detrusor muscle regeneration on | Doxor
pelvi-ureteric junction obstruction in, retroperitoneoscopic dis- (Frederiksen et al), 2659
membered pyeloplasty for (Yeung et al), 1915 Corpus cavernosum Drinki
prostatic utricles in, laparoscopic excision of (Yeung et al), 1921 nitric oxide production and neuronal nitric oxide synthase in,
pyelonephritis in serotonin reuptake inhibitors and (Angulo et al), 2308 Drug(s
DMSA and parenchymal dysfunction in (Sfakianakis et al), 418 smooth muscle of, prostaglandin E receptor activation by prosta-
intravenous antibiotic duration in, renal scarring and (Benador noid synthesis on (Moreland et al), 2308 Drug 1
et al), 1929 Cortisol, serum level of, renal cell carcinoma tumor grade and
pyelo-ureteric junction obstruction in, preoperative parameters (Rasmuson et al), 2653 E400P
and postoperative function (Zaccara et al), 418 Cost analysis, of multidrug-resistant urinary tract infections (Le EGF r
renal tumor in, nephron-sparing surgery for (Cozzi et al), 806 and Miller), 1928 Ejacul
transyerse myelitis in, urinary tract dysfunction after (Ganesan Cranberries, in preventing urinary tract infections (Jepson et al), a2-ar
and Borzyskowski), 2654 1930 in el
ureteropelvic junction obstruction by stones in (Tekin et al), 795 Crossmatching, flow cytometric, in renal transplant recipients prem
urinary incontinence in, in primary school (Sureshkumar et al), 420 (Karpinski et al), 2664 Elderl
urinary tract infection in, incidence and diagnosis of (Jakobsson et Cryopreservation, of sperm Electr
al), 426 DNA integrity and morphology after (Donnelly et al), 2300
urodynamics in, male sex hormone effects on (Celayir et al), 1551 intracytoplasmic injection of (Kuczynski et al), 2300 Embol
vesico-ureteric reflux in, noninvasive test for (Mevorach et al), Cyclin D2 and E, in testicular germ cell tumors (Schmidt et al),
1916 1549 Endop
Cholecystectomy, laparoscopic, capnoperitoneum during (Dexter Cyclin E level, and bladder cancer progression from superficial to in po
et al), 799 invasive (Kamai et al), 2290 stone
Chordee, congenital, corrective surgery for, penile sensation after Cyclin-dependent kinase, in testicular germ cell tumors (Schmidt in sy
(Ghanem et al), 419 et al), 1549 Endos
Chromosomal abnormalities, in ICSI-conceived babies Cyclosporine, in renal transplant patient, late graft loss and (Mar-
(Aboulghar et al), 782 cén et al), 1563 | Endos
(Macas et al), 782 Cysta-Q, for interstitial cystitis (Katske et al), 1559 Endot
Cigarette smoking Cystectomy
erectile dysfunction and, in diabetes (Bortolotti et al), 2308 for bladder cancer, adjuvant chemotherapy after (Sylvester and |E ndov
renal allograft loss and (Sung et al), 1560 Sternberg), 779 |
SUBJECT INDEX TO ABSTRACTS 2673
subtotal, detrusor muscle regeneration after, effects on contractile Environment, male infertility and (Oliva et al), 2298
proteins and bladder mechanics (Frederiksen et al), 2659 Epidermal growth factor receptors, in nonseminomatous germ
lence Cystitis, interstitial cell tumors (Moroni et al), 2646
hematuria significance in (Gomes et al), 1558 Epididymitis, pediatric, investigation after first episode (Cappele
name and diagnostic criteria revisions for (Agarwal et al), olo r et al), 420
pe et quercetin supplement Cysta-Q for (Katske et al), 1559 Epithelial carcinogenesis, prostatic (De Marzo et al), 814
Cystometry method, involuntary detrusor contractions and (Blai- Epithelial cells, hyaluronic acid and HYAL1 hyaluronidase in, as
785 vas et al), 2660 prostate cancer marker (Lokeshwar et al), 2330
ham- Cystoplasty, augmentation (Greenwell et al), 2658 Erectile dysfunction
Cystoscopy, before orthotopic neobladder substitution (Bulbul et angiotensin II plasma level in (Becker et al), 2302
(Sax al), 424 . cavernous and systemic testosterone plasma levels during (Becker
Cystourethroscopy, urodynamics combined with, antibiotic pro- et al), 787
VS et phylaxis for (Cundiff et al), 430 in diabetes
Cytokeratin cigarette smoking and (Bortolotti et al), 2308
in bladder cancer and lymph node metastasis (Jiang et al), 2294 intracavernosal alprostadil for (Heaton et al), 2312
urinary, as bladder cancer marker (Mungan et al), 774 diagnosis and treatment of, family practitioner patterns in
(Rutchik et al), 808
Deep vein thrombosis, prevention with aspirin (Pulmonary Em- in elderly men (Blanker et al), 2299
bolism Prevention Trial Collaborative Group), 1922 epidemiology of (Ansong et al), 807
Lal); Deflazacort, for ureteral stones (Porpiglia et al), 797 gene transfer of prepro-calcitonin gene-related peptide for (Bival-
Detrusor ‘acqua et al), 2304
Her- involuntary contractions of, cystometry method and (Blaivas et al), in hypertension
2660 (Chitaley et al), 2310
564 overactive, intravesical oxybutynin for (Lose and Norgaard), 1557 losartan for (Llisterri et al), 2304
/R1SS- regeneration after subtotal cystectomy, effects on contractile pro- international index of (Gil et al), 2312
teins and bladder inechanics (Frederiksen et al), 2659 nitric oxide synthase gene therapy for, vectors for (Tirney et al),
drug | Diabetes mellitus 2301S,
cigarette smoking and (Bortolotti et al), 2308 . prevalence and correlates of, in Brazil (Moreira et al), 2305
intracavernosal alprostadil for (Heaton et al), 2312 in primary care setting (Gil et al), 2312
undiagnosed, in erectile dysfunction (Sairam et al), 789 after radical prostatectomy, nitric oxide synthase and (Podlasek et
in women, asymptomatic bacteriuria in (Geerlings et al), 428 al), 2310
| Dialysis, tuberculosis and (Eastwood et al), 428 sublingual apomorphine for (Mulhall et al), 791
|Di hydrotestosterone, as transdermal gel, for androgen deficiency traumatic pelvic injury/fracture and (Machtens et al), 2667
, 417 in older men (Ly et al), 2324 undiagnosed diabetes mellitus in (Sairam et al), 789
, 423 Diuretic MAG3 scintigraphy, parenchymal dysfunction and, in in uremic dialysis patients, sildenafil for (Bellinghieri et al), 2306
emo- pediatric pyelonephritis (Sfakianakis et al), 418 vasculogenic, asymptomatic ischemic heart disease in (Kim et al),
_DMSA: see Diuretic MAG3 scintigraphy 787
term DNA image cytometry, in bladder cancer diagnosis (Planz et al), Erythropoietin, dosage of, before radical retropubic prostatectomy
| 771 (Nieder et al), 424
after |D oxazosin, for BPH, a-blcekade discontinuation and (Baldwin et Escherichia coli
al), 1935 extraintestinal pathogenic, canine feces as reservoir of (Johnson et
n on Doxorubicin, bladder cancer cell chemosensitivity to, MMAC1/ al), 427
PTEN induction of (Tanaka et al), 778 multidrug-resistant, urinary tract infection from tena et al),
Drinking water, arsenic in, in Taiwan, transitional cell carcinoma 1926
e in, and (Chiou et al), 2290 Estrogen, lower urinary tract dysfunction and (Hextall and Car-
Drug(s), neurotransmission and effects of, in urethral smooth mus- dozo), 2657
osta- cle (Andersson), 2656 Etoposide, for testicular tumor, sperm aneuploidy after (De Mas et
Drug research, neuro-urological, future direction of (Steers), 2656 al), 785
and Exercises, for pelvic floor muscle, hormone replacement therapy
E400P, advanced seminoma prognosis and (Arija et al), 2648 with, for female urinary incontinence (Ishiko et al), 2657
EGF receptors: see Epidermal growth factor receptors
Ejaculation Familial testicular cancer, racial differences in (Dong et al), 2648
a2-adrenoceptor antagonists and (Yonezawa et al), 2307 Family practitioners, patterns of erectile dysfunction diagnosis
in elderly men (Blanker et al), 2299 and treatment among (Rutchik et al), 808
premature, chronic prostatitis and (Screponi et al), 1933 Fat, injectable autologous, for urinary incontinence in women (Her-
Elderly patients: see Age/aging; Geriatric patients schorn), 1560
Electromotive techniques, mitomycin C administered by (Colom- Feces, canine, as reservoir of extraintestinal pathogenic Escherichia
bo et al), 2295 coli (Johnson et al), 427
Embolism, pulmonary, prevention with aspirin (Pulmonary Embo- Female Intervention Efficacy Index, in sexual dysfunction (Ber-
t al), lism Prevention Trial Collaborative Group), 1922 man et al), 794
Endopyelotomy Females: see also Menopause
al to in poorly functioning kidney (Kapoor et al), 2313 bladder outlet obstruction in (Patel and Nitti), 2658
stone recurrence after (Bernardo et al), 794 community-acquired multidrug-resistant urinary tract infections
midt in symptomatic older child (Nicholls et al}, 1916 in (Gupta et al), 1927
Endoscopic surgery, three-dimensional vision in (Tevaearai et al), diabetic, asymptomatic bacteriuria in (Geerlings et al), 428
Mar- 801 genital sensation in, normative values for (Vardi et al), 1919
Endoscopy, fluorescence, of bladder cancer (Frimberger et al), 1926 sexual dysfunction in
Endothelin-1, vasoconstriction induced by, inhibition in penile clitoral neuropathy and (Sax et al), 793
erection (Mills et al), 789 intervention efficacy index in (Berman et al), 794
and Endoureterotomy, balloon cautery, for ureteral strictures after sildenafil for (Berman et al), 794
renal transplantation (Schwartz et al), 2317 vacuum therapy for (Billups et al), 794
. 2674 SUBJECT INDEX TO ABSTRACTS
tension-free vaginal tape in: see Vaginal tape, tension-free nonseminomatous Hypos
urinary incontinence in EGF receptors in (Moroni et al), 2646 re-op
elevated postvoid residual urine volume in (FitzGerald et al), viable malignant cells after chemotherapy for (Fizazi et al), 1550
1554 pediatric, gonadal and nongonadal, common precursor cell for | spon;
hormone replacement therapy and pelvic floor muscle exercises (Schneider et al), 2647 tubul
for (Ishiko et al), 2657 testicular
injectable agents for.(Herschorn), 1560 chemotherapy for, predictors of response and outcome after (Bal- Hypot
physical therapy for (Arvonen et al), 1556 taci et al), 1548
preoperative urodynamic testing in (Weber and Walters), 1558 regulation of cyclin-dependent kinase, cyclin D2, ad cyclin E in
tension-free vaginal tape for (Nilsson and Kuuva), 2655 (Schmidt et al), 1549
Fertilization in vitro, timing of, ICSI outcome of (Levran et al), 784 testicular malignant, CAG/CTG repeats in (Ono et al), 2646 IL: see
Fetoprotein Glansectomy, for Buschke-Lowenstein tumors of penis (Davis and ‘Ileal n
as marker for germ cell tumors, after chemotherapy (Mazumdar et Schellhammer), 2303
al), 1551 Glomerulonephrosis, idiopathic focal segmental, in renal trans- | Iliac a
as marker for renal cell carcinoma staging and survival (Miyata et plant recipients, plasmapheresis for (Matalon et al), 1561
al), 2322 GnRH: see Gonadotropin-releasing hormone entries Imagi1
FGF: see Fibroblast growth factor entries Gonadotropin-releasing hormone agonist histrelin, hydrogel of bl:
Fibroblast growth factor 2, IL-8 induction of, BPH and (Giri and implanted with, for prostate cancer (Schlegel et al), 1913 Immui
Ittmann), 435 Gonadotropin-releasing hormone agonists, for prostate cancer, }| blad¢
Fibroblast growth factor receptors, expression in BPH (Boget et bone loss after (Stoch et al), 415 uring
al), 1938 Gonadotropin-releasing hurmone receptors, in prostate (Tieva
Fibronectin, urinary, after BCG for bladder cancer (Danisman et et al), 1937 Immu
al), 777 Gracilis muscle flap, tissue engineering with, for bladder substi-
Finasteride tution (Schoeller et al), 2659 Immw
for BPH, a-blockade discontinuation and (Baldwin et al), 1935 Gynecomastia, endocrinology of (Ismail and Barth), 2309 cyclo
saw palmetto herb blend with, tissue effects of, in biopsy (Marks et stero
al), 432 Ha-ras activation, and papillary pathway in formation of urothelial tube!
Fish, fatty, consumption of, prostate cancer and (Terry et al), 1906 tumors (Zhang et al), 2292 Immui
Fistula, renocolic, as xanthogranulomatous pyelonephritis compli- hCG: see Human chorionic gonadotropin
cation (Majeed et al), 1934 Heart disease, asymptomatic ischemic, in vasculogenic erectile dys- In vitr
FK506, in penile neuroprotection (Sezen et al), 1910 function (Kim et al), 787 Incont
Flow cytometric crossmatching, in renal transplant recipients Hematuria, in interstitial cystitis (Gomes et al), 1558 Infant
(Karpinski et al), 2664 ; Hemorrhage, from tension-free vaginal tape procedure (Vierhout), pelvi
Fluorescence endoscopy, of bladder cancer (Frimberger et al), 1555
1926 _Hepsin, as prostate cancer biomarker (Magee et al), 2328 vesic
Force/torque signatures, skills evaluation using (Richards et al), Hereditary prostate cancer, linkage to four susceptibility loci in
801 (Goode et al), 1907 Infect:
Fracture Holmium laser, for prostate resection in BPH (Fraundorfer et al), in pe
pelvic, erectile dysfunction after (Machtens et al), 2667 811 (C:
in renal transplant recipients (Giannini et al), 2665 Hormone replacement therapy (M
FR226807, pharmacological characteristics of (Hosogai et al), 2307 pelvic floor muscle exercise with, for female urinary incontinence unco
FTY720, allograft protection and (Brinkmann et al), 2663 (Ishiko et al), 2657
postmenopausal, non-urinary tract effects of (Manson and Mar- Infert:
Gastrointestinal opioid receptors, postoperative inhibition of tin), 1557 Inforn
(Taguchi et al), 1925 Human chorionic gonadotropin Interf
Gene therapy as marker after chemotherapy for germ cell tumors (Mazumdar et
nitric oxide synthase, for erectile dysfunction, vectors in (Tirney et al), 1551 Interl
al), 2301 spermatogenesis suppression by, in testicular tissues of seminoma Interr
for prostate cancer patient (Hayashi et al), 1548
adenovirus-mediated caspase transfer in (Shariat et al), 2329 Hyaluronic acid and HYAL1 hyaluronidase, stromal and epi-
based on human kallikrein 2 promoter (Xie et al), 2328 thelial expression of, as prostate cancer markers (Lokesh- Taterr
Gene transfer, of prepro-calcitonin gene-related peptide, for erec- war et al), 2330
_ tile dysfunction (Bivalacqua et al), 2304 Hydrocele, excisional, plication, and internal drainage techniques Interr
Genital sensation, female, normative values for (Vardi et al), 1919 for (Ku et al), 1921 (Dur
Genitourinary tract Hydrogel histrelin implant, for prostate cancer (Schlegel et al), (Fro:
arterial-phase imaging of, pitfalls in (Urban and Fishman), 417 1913 Inters
three-dimensional computed tomography of (Leder and Nelson), 17-Hydroxylase, genetic polymorphisms in, in BPH (Schatzl et al), hem
417 433 nam
Geriatric patients: see also Age/aging Hypericin, photodynamic activity of, in bladder transitional cell quer
androgen deficiency in, transdermal dihydrotestosterone gel for carcinoma (Zupk6 et al), 2296 Inters
(Ly et al), 2324 Hyperinsulinemia, BPH and (Hammarsten and Hégstedt), 431
cancer screening in (Walter and Covinsky), 422 Hyperparathyroidism, parathyroidectomy for, sexual! function af- Intraz
erectile and ejaculatory dysfunction in (Blanker et al), 2299 ter (Chou et al), 2305
myocardial infarction in, blood transfusion in (Wu et al), 1922 Hypertension, erectile dysfunction in Intrac
transdermal testosterone in, serum lipid and apolipoprotein levels (Chitaley et al), 2310 chro
and (Whitsel et al), 793 losartan for (Llisterri et al), 2304 from
ultrasound-assisted physical examination of (Siepel et al), 807 Hypogonadal men, intramuscular testosterone esters and plasma
Germ cell tumors lipids in (Whitsel et al), 792 kary
chemotherapy for, hCG and a-fetoprotein serum markers in (Ma- Hypogonadism oute
zumdar et al), 1551 induced in prostate cancer, side effects of (Smith et al), 1914
metastatic, cisplatin neurotoxicity in (von Schlippe et al), 2649 after radiation therapy for prostate cancer (Daniell et al), 413 Intra
SUBJECT INDEX TO ABSTRACTS 2675
| Hypospadias Irrigation fluid, during prostate resection, temperature of, core
re-operative Snodgrass incised plate urethroplasty for (Shanberg body temperature and (Jaffe et al), 423
, 1550 | et al), 421 Ischemic heart disease, asymptomatic, in vasculogenic erectile
ll for | spongioplastic repair of, anatomical basis of (Beaudoin et al), 1917 dysfunction (Kim et al), 787
tubularized-incised plate repair of, uroflowmetry after (Marte et
al), 421 Kallikrein 2 promoter, human, prostate cancer targeted gene ther-
- (Bal- Hypotension-related adverse effects, of a-blockade for BPH apy based on (Xie et al), 2328
(Chrischilles et al), 1936
Karyotyping, abnormal, in ICSI-conceived babies (Aboulghar et al),
1 E in 782 ;
Ki-67, p53 correlation with, in urothelial neoplasia classification
IL: see Interleukin entries - (Cina et al), 772
is and | Ileal neobladder, orthotopic detubularized, spontaneous late rup-
Kidney(s)
ture of (Nippgen et al), 426
polycystic: see Polycystic kidney disease
trans- Iliac artery laceration, from tension-free vaginal tape procedure
poorly functioning, endopyelotomy in (Kapoor et al), 2313
1561 (Zilbert and Farrell), 1556 Kidney cancer, metastatic, postsurgical local progression of (Les et
Imaging: see specific modality al), 2322
jrogel of bladder rupture after blunt trauma (Morey et al), 2667 Kidney transplantation: see Renal transplantation
913 ImmunoCyt test Killer cells, BCG-activated, in vitro generation of (Brandau et al),
ancer, bladder cancer recurrence detection with (Vriesema et al), 1924
778
urinary tract transitional cell carcinoma detection with (Lodde et
Tieva al), 1924
Laparoscopy
Immunophilin ligand FK506, in penile neuroprotection (Sezen et
ubsti- al), 1910 for cholecystectomy, capnoperitoneum during (Dexter et al), 799
Immunosuppression to excise prostatic utricles in children (Yeung et al), 1921
cyclosporine in, late graft loss and (Marcén et al), 1563 local anesthetic infiltration after (Moiniche et al), 800
steroid-free, in preventing allograft rejection (Cole et al), 1562 for nephrectomy
helial tuberculosis and (Eastwood et al), 428 autotransplantation with, for iatrogenic ureteral injury (Shek-
Immunosuppressive acidic protein, as marker for renal cell car- arriz et al), 2316
cinoma staging and survival (Miyata et al), 2322 . open surgical live donor versus (Wolf et al), 2314
e dys- In vitro fertilization, timing of, ICSI outcome of (Levran et al), 784 for nephroureterectomy, in urothelial cell carcinoma (Seifman et
al), 802
Incontinence: see Fecal incontinence; Urinary incontinence
Infants: see also Newborns for radical prostatectomy, urinary incontinence after (Olsson et
al), 1911
hout), pelvi-ureteric junction obstruction in, retroperitoneoscopic dis-
membered pyeloplasty for (Yeung et al), 1915 for retroperitoneal adrenalectomy (Soulié et al), 806
small-bowel occlusion after (Romagnolo and Minelli), 802
vesico-ureteric reflux in, radiology and nuclear medicine cysto-
oci in grams in (McLaren and Simpson), 1917 Laparotomy, after penetrating trauma of torso (Chiu et al), 2668
Infection Laser
et al), in penile prosthesis holmium, for prostate resection in BPH (Fraundorfer et al), 811
(Carson), 2313 for papillectomy, functional effects of (Seifman et al), 796
Laser vaporization, for BPH, economics and (Keoghane et al),
(Montague et al), 2311
2323
nence uncomplicated, in urinary tract, empirical therapy for (Le and
Miller), 2325 Leuprolide implant, for prostate cancer, patient-reported experi-
ence with (Fowler et al), 1913
Infertility, male, environment and (Oliva et al), 2298
LigaSure vessel sealer, in biliary surgery (Matthews et al), 2314
Informed choice, in cancer screening (Welch), 422
Interferon-a, for advanced renal cell carcinoma (Valshampayan et Lipids, blood levels of
dar et al), 2323 ‘ intramuscular testosterone esters and, in hypogonadal men (Whit-
sel et al), 792 :
Interleukin-8, FGF-2 induced by, BPH and (Giri and Ittmann), 435
noma International Germ Cell Cancer Collaborative Group classi- transdermal testosterone and (Whitsel et al), 793
Lithiasis, testicular, as indicator of premalignant conditions (von
fication, of advanced seminoma, E400P and prognosis of
Eckardstein et al), 2300
d epi- (Arija et al), 2648 :
kesh- laternational Index of Erectile Dysfunction, in primary care Lithotripters, third-generation, effects of operator experience and
anesthesia on outcome (EHichel et al), 2318
setting (Gil et al), 2312
‘iques Internists, discussions with patient about cancer screening tests. Losartan, for erectile dysfunction, in hypertension (Llisterri et al),
2304
(Dunn et al), 2326 :
at al), (Frosch et al), 2326 Lycopene supplementation, before radical prostatectomy (Kucuk
Interstitial cystitis et al), 1906
et al), hematuria significance in (Gomes et al), 1558 Lymph nodes, bladder cancer metastasis to, cytokeratin 7 and 20 in
name and diagnostic criteria revisions for (Agarwal et al), 1555 (Jiang et al), 2294
il cell quercetin supplement Cysta-Q for (Katske et al), 1559 Lymphoma, primary renal (Stallone et al), 2650
Interstitial laser coagulation, of prostate, preventing urinary
131 retention after, biodegradable stenting in (Pétas et al), 431 Magnetic resonance angiography, of penis (Pretorius et al), 2303
on af- Intraabdominal pressure, increases in, renal pelvic pressure and Mainz pouch III, for urinary diversion after pelvic irradiation
(Karnak et al), 2651 (Leissner et al), 425
Intracytoplasmic sperm injection Malformations, anorectal, advances in (Pefia and Hong), 1918
chromosomal abnormalities in (Macas et al), 782 Mammography, physician-patient discussions of (Dunn et al), 2326
from fresh versus cryopreserved ejaculated sperm (Kuczynski et Massachusetts Male Aging Study, findings on serum hormones
asma al), 2300 and prostate cancer risk (Mohr et al), 1559
karyotyping of babies conceived through (Aboulghar et al), 782 Megestrol, adrenal insufficiency induced by (Goodman and Cagli-
outcome of, effect of timing of sperm retrieval procedures and in ero), 2652 :
i vitro fertilization on (Levran et. al), 784 Menopause, hormone replacement therapy after, non-urinary tract
13 Intravenous urography, of ureters (Heneghan et al), 416 effects of (Manson and -Martin), 1557
2676 SUBJECT INDEX TO ABSTRACTS
Metabolic parameters, after induced hypogonadism for prostate Nitric oxide pathway, intravenous sildenafil-induced erection in- Penile
cancer (Smith et al), 1914 dependence from (McCauley et al), 790 Penile
Metaiodobenzylguanidine scintigraphy, in pheochromocytoma Nitric oxide production, serotonin reuptake inhibitors and, in a2-ac
localization (Berglund et al), 2651 corpus cavernosum tissue (Angulo et al), 2308 endot
MIBG scintigraphy: see Metaiodobenzylguanidine scintigraphy Nitric oxide synthase
Microarrays, in identifying prostate cancer biomarkers (Grouse et neuronal, serotonin reuptake inhibitors and, in corpus caverno- funct
al), 2327 sum tissue (Angulo et al), 2308 intra
Microlithiasis, testicular, as indicator of premalignant conditions after radical prostatectomy, erectile dysfunction and (Podlasek et
(von Eckardstein et al), 2300 al), 2310 serot
Micturition reflex, tachykinin modulation of (Lecci and Maggi), Nitric oxide synthase gene therapy, for erectile dysfunction,
2655 vectors for (Tirney et al), 2301 varde
Minority populations, prostate cancer in, radiation therapy for NMP22 test: see Nuclear matrix protein 22 test Penile
among (Zietman et al), 810 Nuclear matrix protein 22 test, for urothelial cell carcinoma of (Cars
Mitomycin C bladder (Mian et al), 775 (Mon
administration by thermo-chemotherapy or electromotive tech- Nuclear medicine cystograms, of vesico-ureteric reflux in infants Penile
niques (Colombo et al), 2295 (McLaren and Simpson), 1917
intravesical, improving efficacy of (Au et al), 2294 Penis
MMAC1/PTEN, doxorubicin chemosensitivity induced by, in blad- Oligoarray analysis, of genes in allograft biopsy samples (Akalin et Buse
der cancer cells (Tanaka et al), 778 al), 2666
Mobility, in older men with androgen deficiency, transdermal dihy- Opioid receptors, gastrointestinal, postoperative inhibition of lengt
drotestosterone gel for (Ly et al), 2324 (Taguchi et al), 1925
Molecular genetics, in invasive bladder cancer diagnosis (Krause Oxybutynin, intravesical, for overactive detrusor (Lose and Nor- MRA
et al), 770 gaard), 1557 neur
MRA: see Magnetic resonance angiography
Miillerian inhibiting substance, testosterone synthesis and (Srir- p27*'P! level, and bladder cancer progression from superficial to sensi
man et al), 2299 invasive (Kamai et al), 2290
Multidrug resistance, of Escherichia coli, urinary tract infection p53 stret
from ‘ bladder transitional cell carcinoma prognosis and (Shariat et all),
(Manges et al), 1926 776 Peyro!
community-acquired in women (Gupta et al), 1927 in bladder transitional cell carcinoma recurrence (Friedrich et al), acety
Muscle, invasion by bladder cancer, chemoradiotherapy for (Arias et 2291
al), 2297 Ki-67 correlation with, in urothelial neoplasia classification (Cina cell «
Muscle strength, in older men with androgen deficiency, transder- et al), 772 lipos
mal dihydrotestosterone gel for (Ly et al), 2324 as predictor of response and outcome of chemotherapy for meta-
Myelitis, pediatric transverse, urinary tract dysfunction after static germ cell testicular tumors (Baltaci et al), 1548 Pheoc
(Ganesan and Borzyskowski), 2654 . Paclitaxel, for advanced renal cell carcinoma (Valshampayan et al), local
Myoblast vectors, in nitric oxide synthase gene therapy for erectile 2323
dysfunction (Tirney et al), 2301 Pamidronate, to prevent bone loss during androgen deprivation peric
Myocardial infarction, in elderly patients, blood transfusion in therapy (Smith et al), 1912 Phosp
(Wu et al), 1922 Papillectomy, unilateral laser, functional effects of (Seifman et al),
796 Physi
Neobladder: see also Bladder substitution; Urinary diversion Parathyroidectomy, sexual function after (Chou et al), 2305
orthotopic Parenchymal dysfunction, in pediatric pyelonephritis, DMSA and Physi
detubularized ileal, spontaneous late rupture of (Nippgen et al), (Sfakianakis et al), 418
426 Patient education, in prostate cancer (Feldman-Stewart et al), 809 Plasm
preoperative cystoscopy, prostate biopsy, and urethral biopsy in Patterns of care
(Bulbul et al), 424 of age-specific PSA testing, by primary care physicians (Collins et
Nephrectomy al), 808
hand-assisted laparoscopic versus open surgical live donor (Wolf et of erectile dysfunction diagnosis and management, by family prac-
al), 2314 titioners (Rutchik et al), 808
laparoscopic, autotransplantation with, for iatrogenic ureteral in- in prostate cancer (Chuba et al), 812
jury (Shekarriz et al), 2316 in radiation therapy for prostate cancer, nationally and in
for metastatic renal cell carcinoma (Tigrani et al), 803 minority-rich areas (Zietman et al), 810
Nephrolithiasis, risk factors for, in polycystic kidney disease Pediatric urology: see Children; Infants
(Grampsas et al), 795 Pelvic floor muscle exercises, hormone replacement therapy
Nephron-sparing surgery with, for female urinary incontinence (Ishiko et al), 2657
for renal cell carcinoma, with normal opposite kidney (Filipas et Pelvic irradiation, urinary diversion after, Mainz pouch III for
al), 803 (Leissner et al), 425
for renal tumor in children (Cozzi et al), 806 Pelvic organ prolapse, in women, preoperative urodynamic test-
Nephroureterectomy, laparoscopic versus open, for urothelial cell ing in (Weber and Walters), 1558
carcinoma (Seifman et al), 802 Pelvic pressure, renal, and increases in intraabdominal pressure
Neuromodulation, of bladder, in spinal cord-injured patient (Karnak et al), 2651
(Kirkham et al), 1555 Pelvic thrusting, a2-adrenoceptor antagonists and (Yonezawa et
Neuroprotection, penile, immunophilin ligand FK506 in (Sezen et al), 2307
al), 1910 Pelvic trainer, three-dimensional vision in (Tevaearai et al), 801
Neuro-urology drug research, future direction of (Steers), 2656 Pelvis, computed tomography of, pitfalls in (Urban and Fishman),
Newborns > 417
circumcision of, effect on urinary tract infection cost and incidence Pelvi-ureteric junction obstruction, in infants and children, ret- Prost:
(Schoen et al), 1930 reperitoneoscopic dismembered pyeloplasty for (Yeung et | insti
male, reproductive hormone role in (Main et al), 1919 al), 1915
Nifedipine, for ureteral stones (Porpiglia et al), 797 Penetrating trauma, of torso, laparotomy in (Chiu et al), 2668 intré
SUBJECT INDEX TO ABSTRACTS 2677
ion in- Penile curvature: see Chordee Prostaglandin E receptors, activation by prostanoid synthesis, on
Penile erection corpus cavernosum smooth muscle (Moreland et al), 2308
nd, in a2-adrenoceptor antagonists and (Yonezawa et al), 2307 Prostanoid synthesis, prostaglandin E receptor activation by, on
endothelin-1-induced vasoconstriction inhibition in (Mills et al), corpus cavernosum smooth muscle (Moreland et al), 2308
789 Prostate
verno- functional measurement of (Hellstrom), 792 interstitial laser coagulation of, preventing urinary retention af-
intracavernous sildenafil and, nitric oxide pathway and (McCauley ter, biodegradable stenting in (Pétas et al), 431
isek et et al), 790 thermal therapy of, transurethral and interstitial ultrasound ap-
serotonin reuptake inhibitors and, in corpus cavernosum tissue plicators for (Diedrich et al), 432 :
action, (Angulo et al), 2308 transperineal interstitial permanent brachytherapy of, antibiotic
vardenafil hydrochloride for (Bischoff and Schneider), 792 prophylaxis in (Dicker et al), 430
Penile prosthesis, infection in transurethral resection of
yma of (Carson), 2313 for BPH, economics and (Keoghane et al), 2323
(Montague et al), 2311 PSA reference range after (Wolff et al), 436
nfants Penile skin onlay flap, for urethral stricture, placement of (Bhan- Prostate androgen quantification, biopsy for, tissue effects of
dari et al), 1564 saw palmetto herb blend with finasteride in (Marks et al),
Penis 432
alin et Buschke-Lowenstein tumors of, glansectomy for (Davis and Schell- Prostate biopsy
hammer), 2303 after brachytherapy, PSA rise and
ion of length of, change in after radical retropubic prostatectomy (Mund- (Grimm et al), 412
ing et al), 1911 (Smathers et al), 412
1 Nor- MRA imaging of (Pretorius et al), 2303 before orthotopic neobladder substitution (Bulbul et al), 424
neuroprotection of, immunophilin ligand FK506 in (Sezen et al), Prostate cancer
1910 androgen deprivation therapy for: see Androgen deprivation ther-
cial to sensation in, after surgery for congenital chordee (Ghanem et al), apy
419 androgen-independent, thalidomide for (Figg et al), 1914
stretched length of, after radical retropubic prostatectomy (Mund- bicalutamide for
et al), ing et al), 2303 after failed hormone therapy (Kucuk et al), 415
Peyronie’s disease recurrence and (Wirth et al), 414
et al), acetyl-L-carnitine versus tamoxifen for (Biagiotti and Cavallini), biomarkers for
788 hepsin as (Magee et al), 2328
(Cina cell cycle regulator perturbation in (Mulhall et al), 2311 microarray approaches to (Grouse et al), 2327
liposomal recombinant human superoxide dismutase for (Riedl et stromal and epithelial hyaluronic acid and HYAL1 hyaluroni-
meta- al), 2309 dase as (Lokeshwar et al), 2330
8 Pheochromocytoma death from, after PSA mass screening (Bartsch et al), 1909
et al), localization of, MIBG scintigraphy and CT in (Berglund et al), fatty fish consumption and (Terry et al), 1906
2651 gene therapy for
vation perioperative morbidity and mortality in (Plouin et al), 1552 adenovirus-mediated caspase transfer in (Shariat et al), 2329
Phosphodiesterase type 5 inhibitor FR226807, pharmacological based on human kallikrein 2 promoter (Xie et al), 2328
et al), characteristics of (Fosogai et al), 2307 GnRH agonists for, bone loss after (Stoch et al), 415
Physical examination, ultrasound-assisted, of geriatric patients hereditary, linkage to four susceptibility loci in (Goode et al), 1907
5 (Siepel et al), 807 hormonal management of (Bondy et al), 811
SA and Physical therapy, for urinary incontinence in women (Arvonen et induced hypogonadism side effects in (Smith et al), 1914
al), 1556 intralesional TRAIL adenovirus treatment for (Griffith and
1), 809 Plasmapheresis, for idiopathic focal segmental glomerulonephrosis Broghammer), 2329
in renal transplant recipients (Matalon et al), 1561 leuprolide implant for, patient-reported experience with (Fowler et
lins et Plasmid vectors, in nitric oxide synthase gene therapy for erectile al), 1913
dysfunction (Tirney et al), 2301 markers of, truncated precursor form of PSA as | Mikolajezyk et al),
y prac- PMSA: see Prostate specific membrane antigen 1908
Polycystic kidney disease, nephrolithiasis risk in (Grampsas et mortality from, in Japan (Imaizumi), 408
al), 795 patient questions regarding (Feldman-Stewart et al), 809
nd in Polyurethane stent, ureteral, severe crusting of (Singh et al), 2317 patterns of care in (Chuba et al), 812
Pregnancy population-based screening for, male refusal to attend (Nijs et al),
asymptomatic bacteriuria in 809
verapy antibiotics for (Smaill), 1932 predicting risk from PSA level, longitudinal aging study of (Fang
duration of treatment for (Villar et al), 1931 et al), 1907
lower urinary tract changed during (Wijma et al), 2653 PSA in
outcome of, in spina bifida patients (Arata et ai), 1918 age and rectal examination with (Potter et al), 400
Prepro-calcitonin gene-related peptide, gene transfer of, for routine bone scan indications in (Wymenga et al), 410
erectile dysfunction (Bivalacqua et al), 2304 radiation therapy for
essure Preputial skin onlay flap, for urethral stricture, placement of hypogonadism after (Daniell et al), 413
(Bhandari et al), 1564 patterns of use nationally and in minority-rich areas (Zietman et
wa et Primary care physicians, age-specific PSA testing patterns al), 810
among (Collins et al), 808 recurrence after androgen deprivation therapy, androgen receptor
|, 801 Primary care setting, erectile dysfunction in (Gil et al), 2312 mechanisms in (Gregory et al), 2650
yman), Prognostic factor studies in urology, statistical problems in recurrence of
(Keegan et al), 770 prevention with bicalutamide (Wirth et al), 414
n, ret- Prostaglandin E risk model for (Roberts et al), 411
ing et instillation versus injection of, penile cavernosal artery and (Kim salvage radiation therapy for (Leventis et al), 411
et al), 786 risk of, serum hormones and (Mohr et al), 1559
568 intraurethral, consistency in at-home use (Mulhall et al), 786 screening for, tumor characteristics in (Vis et al), 408
. 2678 SUBJECT INDEX TO ABSTRACTS
serum:urinary PSA ratio in (Hillenbrand et al), 436 Pulmonary embolism, prevention with aspirin (Pulmonary Embo- Renal
tumor growth and metastasis of, inhibition by prostate stem cell lism Prevention Trial Collaborative Group), 1922
antigen (Saffran et al), 813 Purinoceptor expression, in bladder neck obstruction (O’Reilly et Renal :
Prostate cancer screening, PSA in, after antibacterial therapy for al), 2656
prostate inflammation (Karazanashvili and Managadze), Pyelonephritis Renal |
1932 in children bone
Prostate carcinogenesis, epithelial (De Marzo et al), 814 DMSA and parenchymal dysfunction in (Sfakianakis et al), 418 flow «
Prostate gland, GnRH receptors in (Tieva et al), 1937 intravenous antibiotic duration in, renal scarring and (Benador glome
Prostate hyperplasia, benign: see Benign prostatic hyperplasia et al), 1929 reject
Prostate inflammation, PSA after antibacterial therapy for, pros- xanthogranulomatous, renocolic fistula as complication of (Majeed
tate cancer detection and (Karazanashvili and Managadze), et al), 1934 silder
1932 Pyeloplasty, retroperitoneoscopic dismembered, for pelvi-ureteric tuber
Prostate resection, core body temperature during, irrigation fluid junction obstruction in infants and children (Yeung et al), Renal |
temperature and (Jaffe et al), 423 1915 allogi
Prostate specific antigen Pyelo-ureteric junction obstruction, in children, preoperative cig:
age-specific testing of, patterns among primary care physicians parameters and postoperative function (Zaccara et al), 418 aft
(Collins et al), 808 dono!
after antibiotics for prostate inflammation, prostate cancer detec- Quality control, of radical prostatectomies (Van Poppel et al), 410 shipp
tion and (Karazgnashvili and Managadze), 1932 Quality of life
after brachytherapy in older men with androgen deficiency, transdermal dihydrotest- urete
effectiveness of (Grimm et al), 412 osterone gel for (Ly et al), 2324
repeat prostate biopsy and (Smathers et al), 412 urinary tract symptoms and, in BPH Renal |
in cancer screening, physician-patient discussions of (Eckhardt et al), 434
(Dunn et al), 2326 (van Venrooij et al), 434 Renoc:
(Frosch et al), 2326 Quercetin supplement Cysta-Q, for interstitial cystitis (Katske et
al), 1559 Repro
as indication for transition zone biopsy (Liu et al), 409
cis-Ret
in mass screening, prostate cancer death after (Bartsch et al), 1909
predicting prostate cancer risk from, longitudinal aging study of Racial differences, in testicular cancer (Dong et al), 2648
Radiation oncologists, practice patterns for androgen ablation
(Fang et al), 1907
after radiation therapy failure (Sylvester et al), 2325 Sacral
prostate cancer and
Radiation therapy
age and rectal examination with (Potter et al), 408
failure of, androgen ablation after, practice patterns of urologists Saw p
routine bone scan indications in (Wymenga et al), 410
and radiation oncologists in (Sylvester et al), 2325
reference range of, after transurethral resection of prostate (Wolff
pelvic, urinary diversion after, Mainz pouch III for (Leissner et al), Semen
et al), 436
425 paral
serum:urinary ratio of, in BPH and prostate cancer (Hillenbrand
for prostate cancer
et al), 436 hypogonadism after (Daniell et al), 413 quali
truncated precursor form of, as prostate cancer marker (Mikolaje-
patterns of use nationally and in minority-rich areas (Zietman et Semin
zyk et al), 1908
al), 810 adva
Prostate specific membrane antigen, in neovasculature of met-
salvage, for postoperative recurrent prostate cancer (Leventis et testic
astatic renal cell carcinoma (Chang et al), 804 al), 411 eal
Prostate stem cell antigen Radiography, of vesico-ureteric reflux in infants (McLaren and hC
prostate cancer tumor growth and metastasis inhibition by (Saff- Simpson), 1917 Seque
ran et al), 813 Rectal examination, in prostate cancer screening
in transitional cell carcinoma (Amara et al), 813 age, PSA and (Potter et al), 408 Seroto
Prostate utricles, in children, laparoscopic excision of (Yeung et
tumor characteristics and (Vis et al), 408
al), 1921
Rejection of renal allograft, steroid-free immunosuppression in
Prostatectomy (Cole et al), 1562 Sex he
radical REM sleep deprivation, sexual behavior and (Ferraz et al), 2301 effect
cancer recurrence after Renal agenesis, in congenital absence of vas deferens (McCallum et prost
risk model for (Roberts et al), 411 al), 781. Sexua’
salvage radiation therapy for (Leventis et al), 411 Renal carcinoma, tumor M2 protein kinase in (Oremek et al), 804 clitor
erectile dysfunction after, nitric oxide synthase and (Podlasek et Renal cell carcinoma inter
~ al), 2310 adrenal metastasis of, incidence and outcome of (Paul et al), 1554 silde
lycopene supplementation before (Kucuk et al), 1906 advanced, paclitaxel, a-interferon, and cis-retinoic acid for vacu
quality control of (Van Poppel et al), 410 (Valshampayan et al), 2323 Sexua
radical laparoscopic, urinary incontinence after (Olsson et al), familial clear cell, genetic mutation analysis of (Woodward et al), effec
1911 805
radical retropubic metastatic after
capsular incision in, prognosis and (Barocas et al), 1910 neovasculature of, PSMA in (Chang et al), 803804 sping
changes in penile length after (Munding et al), 1911 nephrectomy for (Tigrani et al), 803 in sf}
preoperative erythropoietin dosage in (Nieder et al), 424 nephron-sparing surgery for, with normal opposite kidney (Filipas
recurrence of, risk model for (Roberts et al), 411 et al), 803 Shock
stretched penile length after (Munding et al), 2303 nonmetastatic, prognostic assessment of (Yaycioglu et al), 2321
urinary catheter removal after (Lepor et al), 1912 staging and survival in, markers for (Miyata et al), 2322 Silden
Prostatitis, chronic tumor grade in, serum cortisol levels and (Rasmuson et al), 2653 for e
allopurinol for (Collins and Wilt), 1933 Renal cells, differentiation and growth arrest in, induction by von
premature ejaculation and (Screponi et al), 1933 Hippel-Lindau gene (Davidowitz et al), 805 for fe
Proteins, contractile, effect of detrusor muscle regeneration on (Fre- Renal function, substitution through skin catharsis (Diamando- intra
deriksen et al), 2659 poulos and Goudas), 2652
PSA: see Prostate specific antigen Renal lymphoma, primary (Stallone et al), 2650 in re